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Introduction. 
In 2012 there were more than 40,000 new cases of lung cancer in the UK [1]. In the treatment of this 
disease radiotherapy is a central treatment modality [2]. In spite of significant technical developments 
in the radiotherapy, local recurrence rates following curative intent radiotherapy in the treatment of 
non-small cell lung cancer (NSCLC) remain high [3]. Radiation dose escalation is one potential avenue 
of optimisation, but is limited by adjacent normal tissue tolerances [4]. Another strategy to optimise 
the biological effectiveness of radiotherapy is by co-administration of therapeutic agents that 
preferentially sensitize malignant cells to radiotherapy. Combining cytotoxic chemotherapy with 
radiotherapy is such a strategy and has been shown to improve both local control rates and overall 
survival [5,6]. However, the therapeutic gain achieved by adding cytotoxic chemotherapy to 
radiotherapy is modest (4.5% gain in overall survival at 5 years with concurrent versus sequential 
chemotherapy) and is associated with increased toxicity [6]. With increasing understanding of the 
molecular mechanisms underlying radioresistance and the emergence of systemic agents that can 
target these mechanisms there is growing interest in considering what additional benefit these agents 
may add to radiotherapy and how to combine the two modalities in the most effective manner.  
 
This strategy of optimising radiotherapy with systemic therapy is principally aimed at those patients 
whose disease is localised and potentially curable. However radiotherapy is also used for palliation of 
local symptoms in patients with advanced or metastatic disease [7]. In this patient group, investigators 
are starting to evaluate how radiotherapy may be used to optimise the efficacy of systemic therapies 
such the immune modulating agents. This concept in considered in more detail in another paper in 
this special edition [8].  
 
In this article we consider aspects of tumour biology and radioresistance which can be exploited by 
novel agents delivered in combination with radiotherapy, and the important issues to be considered 
when combining novel agents with radiotherapy in clinical studies. To illustrate these issues and 
present potential solutions, we report on the consensus reached at a National Cancer Research 
Institute (NCRI) Clinical Translational Radiotherapy Research Working Group (CTRad) workshop, held 
in Glasgow in February 2016, and the resulting plans to develop two umbrella study platforms to 
successfully test and implement such novel radiotherapy combinations.  
 
Current systemic therapy combinations with radiotherapy in the management of NSCLC. 
At present, concurrent systemic therapy has no established role in combination with radiotherapy in 
the curative treatment of stage I or II NSCLC. However, approximately one third of patients when 
diagnosed with NSCLC have locally advanced, stage IIIA or IIIB disease, for whom curative surgical 
treatment is not an option [9]. Those patients who have a good performance status and acceptable 
lung function can usually be treated with curative intent radiotherapy, and the addition of 
chemotherapy has been shown to improve outcomes in this population [10]. Radiotherapy as a single 
agent may be offered to patients whose fitness or comorbidities preclude the use of chemotherapy 
either as induction treatment or concurrent with radiotherapy. In the last decade there has been a 
shift to using platinum chemotherapy concurrently with high dose radiation, based on data showing 
better outcomes when compared with induction chemotherapy [6]. However, this approach is suitable 
for less than half of patients with locally advanced NSCLC [11,12].  
 
Concurrent chemo-radiotherapy is associated with an improvement in survival [6]. Although some 
discrepancies in practice exist, the preferred chemotherapy regimen is usually based on a platinum-
containing doublet [2]. The optimum radiotherapy dose and fractionation to combine with systemic 
treatment is less clear. Currently most reported regimens deliver 2 Gy per fraction, 5 days per week, 
to a total dose of 60-66Gy.  
 This issue has been the subject of a number of clinical trials.  Most recently the results of the RTOG 
0617 study were reported, in which patients were randomised to 60Gy in 6 weeks versus 74Gy in 7.5 
weeks and, in a 2x2 design, were also randomised to the addition or not of cetuximab to concurrent 
platinum based  chemotherapy [13]. Patients in the 74 Gy arm had poorer survival than those in the 
lower dose arm (20.3 months versus 28.7 months). The addition of cetuximab for all comers in this 
cohort did not improve survival, which has been a disappointing finding, given encouraging prior 
results from the SCATCH pilot study [14]. The outcomes of this trial have undermined the validity of 
dose escalation alone, using conventional fractionation, as a method to improve local control or 
survival in NSCLC [15].  
 
Another approach to improving outcomes for patients with locally advanced NSCLC is to alter 
radiotherapy fractionation, either by increasing the number of fractions delivered each day, delivering 
the radiation over a shorter period of time (acceleration), or a combination of the two [4, 16]. 
Conversely, achieving acceleration by increasing the radiation dose per fraction (hypofractionation) in 
stage III NSCLC has also been investigated and in the SOCCAR phase II randomised trial, 55Gy in 20 
fractions over four weeks was evaluated in combination with cisplatin and vinorelbine chemotherapy 
delivered either concomitantly or sequentially [17]. In this study the median survival was 24.3 months 
in the concurrent setting compared to 18.4 months in the sequential arm and there has been much 
interest and progress in combining other modified fractionation regimens with cytotoxic 
chemotherapy [18,19] 
 
Potential therapeutic targets to enhance radiotherapy effectiveness. 
In describing the revised hallmarks of cancer, Hanahan and Weinberg provide a useful framework 
within which to consider mechanisms through which to increase the tumoricidal effects of radiation 
[20]. Many of these approaches have mechanistic potential to enhance radiation induced lethal 
damage within the tumour cell and are presented in table 1 [21-28]. It should be noted that a number 
of studies examining the combination of novel or targeted agents with radiotherapy in NSCLC are 
underway [29]. 
 
Table 1: Hallmarks of cancer and potential mechanisms to enhance effect of radiotherapy (adapted 
from Hanahan and Weinberg [17]). 
 
Hallmark of Cancer Potential mechanism for 
enhancement of radiation effect 
Therapeutic agents for 
consideration 
Genomic instability and mutation Radiation induced DNA damage is  
augmented by inhibition of DNA 
damage repair processes 
PARP inhibition, ATM inhibition, 
ATR inhibition and Wee1-kinase 
inhibition [21] 
Tumour promoting inflammation Paracrine cell signalling which 
switches on survival pathways is 
blocked leading to reduced cell 
survival   
CXCR2 inhibition [22] 
Enabling replicative immortality Malignant cell ability to cope with 
telomere damage from 
radiotherapy is reduced 
Telomerase inhibitors [23] 
Avoiding immune destruction Radiation induced inflammation 
within the tumour is detected by 
activated T-cells which in turn 
leads to anti-tumour adaptive 
immune response 
Immune modulating agents (e.g. 
CTLA4, PD-1, PD-L1 checkpoint 
inhibitors) [24] 
Resisting Cell Death Therapeutic agent overcomes 
tumour cell ability to avoid 
apoptosis following radiotherapy  
BH3 mimetics, cFLIP inhibition 
[25] 
Evading Growth Suppressors Proliferative potential after 
exposure to radiation is reduced 
or terminated 
Cyclin Dependent Kinase 
Inhibitors [26] 
Sustaining Proliferative Signalling Following radiation the tumour 
cell proliferative signalling 
response is reduced which 
triggers apoptosis 
EGFR inhibitors [27] 
Deregulating Cellular Energetics AKT-mediated enhanced aerobic 
glycolysis radioresistance within 
tumour cells is reduced 
Aerobic Glycolysis inhibitors [28] 
 
 
Challenges when designing clinical studies evaluating novel agent/radiotherapy combinations. 
Central to the premise of more targeted therapy is an understanding of the molecular characteristics 
of each patient’s tumour. Molecular sub-typing has transformed treatment pathways for the systemic 
management of advanced NSCLC [30] and it is likely that molecular subtyping will be essential in 
determining the appropriate systemic therapy agent to combine with radiotherapy for a given patient. 
Molecular sub-typing is currently reliant on tissue blocks rather than cytological sample, but many 
novel methods that seek to optimise molecular analysis are under development [31]. In general, 
molecular sub-typing requires biopsy samples that are representative of the tumour and of sufficient 
size to permit analysis. Given the impact that tumour biology is likely to have on novel drug and 
radiotherapy combinations, it is critical that clinical trials in this area include carefully considered, 
biologically relevant translational components. One challenge is the high degree of tumour 
heterogeneity that appears to characterise NSCLC in comparison to other primary tumour sites; the 
degree to which this will influence response to novel drug/radiotherapy combinations is not yet known 
but should certainly be borne in mind [32]. 
 Innovative trial design will also be key to the success of future drug/radiotherapy combination studies 
in NSCLC [33]. One of the key dose limiting toxicities in these patients is pneumonitis, and the timings 
and severity of this side effect are variable and poorly understood. The majority of patients who will 
go on to develop late pneumonitis after radiotherapy have measurable signs or symptoms by 3 to 6 
months after completion of radiotherapy [34]. In early phase trials of a novel combination, there is a 
competing interest between ensuring that any increases in late toxicity are detected and acted upon 
and the objective of completing the study in the shortest possible time. The concept of using predicted 
risks and Bayesian models to estimate anticipated toxicity at given time points can be using to 
accelerate trial recruitment in a safe and robust manner [35]. Of particular interest is the time-to-
event continual reassessment method [36], a methodology that has been used in clinical trials of novel 
radiotherapy-drug combinations in other disease settings [37] and is increasingly viewed as the most 
appropriate study design in this research field. 
 
Finally, with regard to trial design, the end-points by which clinical efficacy of the radiotherapy-drug 
combination are assessed need to be carefully considered. Pseudo-progression of the apparent 
disease in the irradiated field is a well-recognised clinical entity after both conventional 
chemoradiotherapy and stereotactic ablative body radiotherapy [38,39]. Any potential studies in this 
area will need have mechanisms to take pseudo-progression into account and may need to consider 
the more robust end-point of overall survival when assessing clinical efficacy. This and other relevant 
issues are covered in more detail in the Consensus Statement on clinical development of new drug-
radiotherapy combinations that was recently published in Nature Reviews Clinical Oncology [40]. 
 
 
NRCI CTRad UK Consensus on radiotherapy-drug combination studies in NSCLC. 
Recognising both the opportunities and the challenges in this area, and the importance of an 
integrated, multidisciplinary approach, NCRI CTRad organised a two day workshop at the Beatson 
West of Scotland Cancer Centre, Glasgow, in February 2016. This was attended by clinical and medical 
oncologists specialising in the treatment of lung cancer, along with methodologists, statisticians, 
scientists and industry partners from across the UK. After a review of the current clinical trials portfolio 
it was agreed that there was both a requirement and an important opportunity to develop high quality 
clinical trials to evaluate novel drug-radiotherapy combinations. In addition it was considered that the 
NCRI Lung Clinical Studies Group should support the development and implementation of these 
studies.  
 
One of key aims of the meeting was to decide which radiotherapy regimen should be used for any 
novel combinations with curative intent radiotherapy. After considerable discussion the group agreed 
that the radiotherapy backbone of any novel drug radiation combination study with curative intent 
should utilise a standard 2 Gy fractionation. The rationale behind this decision was that 2 Gy per 
fraction regimes are known to be relatively safe, are well documented and their radiobiology is very 
well characterised, in terms of both tumour and normal tissue effects. Although both 
hyperfractionated accelerated and hypofractionated radiotherapy schedules may be more effective 
that 2 Gy per daily fraction regimens,  the attendees felt that altered fractionation regimes were less 
well characterised and might be associated with increased risks of additional toxicity when combined 
with novel agents. It was agreed that the phase 1 studies combining novel agents with radiotherapy 
should have toxicity measures as their primary end points and as such it was felt that the radiotherapy 
dose should not be escalated. Furthermore using 2 Gy per fraction would permit international 
comparison of results. Of course, testing of any novel agent with altered fractionation should be 
possible at a later stage. Discussion of the minimum technical requirements for planning and 
delivering radiotherapy to potential study patients led to the conclusions that all patients should have 
a 4DCT planning scan and their treatment should be delivered by IMRT with image guidance for 
treatment verification.  
 
It became clear that there were essentially two patient populations in which further investigation was 
warranted, and that two scientific themes held the most potential. In patients with stage III disease 
there is an opportunity to investigate inhibitors of the DNA damage response (DDR) in combination 
with curative intent radiotherapy, while in patients with stage IV disease the combination of 
radiotherapy with immunomodulating agents is of most interest. 
 
Proposed study in stage III NSCLC 
It was agreed that the study of DDR inhibitors in combination with radical radiotherapy for stage III 
NSCLC should be a phase I study designed along the lines of the ongoing Lung MATRIX study in an 
umbrella type concept (see figure 1) [41]. The most suitable patients for this study will be those who 
are fit enough to undergo radical radiotherapy, with or without prior induction chemotherapy, 
however patients who are suitable for concurrent chemo-radiotherapy would not be included because 
of the established risk of exacerbating normal tissue toxicities when combining DDR inhibition with 
concomitant chemoradiation. In this population a performance status of 0 to 2 would be acceptable 
for inclusion, as long as PS2 is due to disease and not comorbidities. A radiotherapy treatment dose 
of 60-66 Gy in 30-33 fractions was recommended, with the total dose determined by key ‘organ at 
risk’ dose constraints according to the isotoxic dose escalation concept [42]. By standardising the dose 
delivered to the critical normal tissues, this approach would ensure that any additional normal tissue 
toxicity detected would reflect the impact of the novel drug rather than discrepancies in radiotherapy 
dose.  
  
Figure 1: Outline of a the planned phase I multi-arm drug dose escalation study of molecularly 
targeted agents in combination with radical radiotherapy for patients with stage III NSCLC 
 
A standard phase 1 trial design will not be optimal to permit patient accrual in any novel agent and 
radiotherapy study design. Furthermore, given the competing morbidities that patients with lung 
cancer face, there is the potential to over- or under-estimate important toxicities form the novel 
combination, thus novel trial design is imperative [43]. This phase I drug dose escalation study will use 
a TITE-CRM or similar Bayesian design to maximise accuracy and value of all relevant toxicity data, 
including acute, subacute and late effects. The primary outcome measure for each arm will be the 
recommended phase II dose of each drug to take forward. It was agreed that a comparative arm 
including patients with similar characteristics and treated with the same dose fractionation will 
facilitate the causality assessment for adverse drug-radiotherapy event. Initially, the umbrella study 
will consider drugs from the AstraZeneca DDR inhibitor portfolio, given the favourable potential 
mechanism of synergy and promising results from other tumour sites (e.g. PARP inhibitor, Wee1 
Kinase inhibitor, ATR inhibitor, ATM inhibitor) [21]. Additional drugs may be added after the study is 
successfully initiated. The study will also incorporate ‘proof of mechanism’ biomarkers where possible 
which have the mechanistic potential to assess the status of key DDR genes which may be critical in 
response to both the DDR agents and to radiotherapy (e.g. the Almac Diagnostics DNA Damage 
Repair Deficiency assay – DDRD) [44]. If future biomarkers become available that have the potential 
to enrich any of the relevant arm(s) of the study, these will be incorporated in an adaptive design. It 
was recommended that the study should use a centralised pharmacy.  
 
Proposed study in stage IV NSCLC  
The design of this study proved to be particularly challenging. A phase II multi-arm study of 
immunomodulatory agents in combination with radiotherapy was considered to be an attractive study 
for patients with stage IV NSCLC. Stage III NSCLC patients who are unsuitable for treatment with 
curative intent might form an additional cohort. It was agreed that patients should have received 
standard first line systemic therapy prior to enrolment. This would be followed by a stratification 
based on the indication for palliative radiotherapy as shown in figure 2. Three possible radiotherapy 
strategies were identified: standard palliative radiotherapy (20 Gy in 5 fractions) to sites of metastatic 
disease, stereotactic ablative radiotherapy to sites of metastatic disease and higher dose palliative 
radiotherapy (36 Gy in 12 fractions) to the primary site. In terms of the immunomodulatory drugs 
being considered there is a growing body of phase I radiotherapy combination data for several agents 
including key candidates such as the immune checkpoint modulators including inhibitors of the 
programmed death receptor and its ligand 1 (PD-1 and PD-L1) [20]. It is likely that a variety of different 
drugs will be included in the various arms. 
 
 
 Figure 2: Outline of the planned phase II multi-arm study of immunomodulatory agents in 
combination with radiotherapy for patients with stage IV NSCLC 
 
 
Conclusions 
During the meeting there was a national enthusiasm for evaluating novel radiotherapy-drug 
combinations in NSCLC. The UK lung cancer clinical community has agreed a consensus on how to 
accelerate the clinical development of novel agents in combination with radiotherapy in this cancer of 
unmet need. Key issues that had previously been contentious were discussed, such as the most 
suitable radiotherapy dose for the radical setting, and agreement reached on how best to proceed. A 
multicentre, multidisciplinary consortium of researchers has begun the task of designing and 
assembling the necessary trial infrastructure and our aim is to fund and open the suggested studies 
within the next two years. 
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